絞り込み

16545

広告

1083件中 101件~120件表示    検索結果をPubMedで見る PubMedで見る

First reported case of afatinib-associated toxic megacolon.

Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor ()-mutant lung adenocarcinoma.

Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock.

Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.

Tissue and Blood Biomarkers in Lung Cancer: A Review.

Author Correction: Genetically engineered cerebral organoids model brain tumor formation.

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.

Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature.

Development and validation of an ELISA with high sensitivity for therapeutic monitoring of afatinib.

Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.

Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Activity of Afatinib in Heavily Pretreated Patients with HER2 Mutation-Positive Advanced NSCLC: Findings from a Global Named Patient Use Program.

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

Osimertinib.

Afatinib.

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.

Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.

  1. 2
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11
Sort by
※並べ替えは表示に時間がかかります